OpenEvidence vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
OpenEvidence hit $100M+ ARR in under a year serving 430K+ US physicians (40% of all US doctors) at $12B valuation ($700M raised); fastest-growing physician AI platform, founded 2022 Miami.
About
OpenEvidence is an AI clinical evidence platform founded in 2022 and headquartered in Miami, Florida. Built specifically for physicians, the platform applies large language models trained on peer-reviewed medical literature to deliver instant, evidence-backed answers to clinical questions at the point of care. Its founding mission is to democratize access to the best available medical evidence so that every physician can practice at the highest standard, regardless of institution or specialty.\n\nThe platform aggregates and synthesizes peer-reviewed studies, clinical guidelines, and drug databases, presenting structured answers with citations that meet physician-grade accuracy standards. Unlike general-purpose AI assistants, OpenEvidence is purpose-built for clinical workflows. It is free to use for physicians, with monetization routed through pharmaceutical and healthcare industry partners who value the platform's direct access to practicing clinicians.\n\nOpenEvidence has achieved remarkable traction, reaching over 430,000 US physicians — approximately 40% of the entire US physician population — making it the fastest-growing physician AI platform on record. The company crossed $100M ARR in under a year from launch and earned a $12 billion valuation on $700 million in total funding. This trajectory places OpenEvidence among the fastest-scaling healthcare AI companies globally and signals a structural shift toward AI-assisted clinical decision-making at the point of care.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.